Amorfix Test for vCJD achieves 100% specificity on 20,000 blood donations in France

25-Jun-2009 - France

Amorfix Life Sciences announced it has tested 20,000 blood donations in France using its EP-vCJD™ blood screening test as part of a large-scale study to demonstrate the feasibility of routine testing of blood donations for vCJD (variant Creutzfeldt-Jakob disease). At the UK specification of a required sensitivity of 1:100,000 dilution of vCJD brain, the Amorfix test was 100% specific with no false positive samples on repeat testing. According to the company, the test performed five times better than required as it was still 100% specific at a sensitivity of 1:500,000 dilution of vCJD brain. At the maximum sensitivity of 1:1,000,000 dilution of vCJD brain, the test was 99.90% specific which exceeds the 99.85% specificity required by the UK Blood Transfusion Service.

Other news from the department research and development

More news from our other portals